Compare NGNE & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | VTEX |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 755.3M |
| IPO Year | 2014 | 2019 |
| Metric | NGNE | VTEX |
|---|---|---|
| Price | $35.99 | $3.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $63.57 | $5.97 |
| AVG Volume (30 Days) | 174.1K | ★ 929.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.78 |
| Revenue Next Year | N/A | $9.63 |
| P/E Ratio | ★ N/A | $43.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $2.84 |
| 52 Week High | $43.66 | $4.73 |
| Indicator | NGNE | VTEX |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 39.79 |
| Support Level | $31.83 | $3.73 |
| Resistance Level | $43.66 | $4.20 |
| Average True Range (ATR) | 2.07 | 0.19 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 72.75 | 14.86 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.